GET DAILY SIGNALSPasithea Therapeutics (KTTA) Climbs +31% on FDA Clearance for Neurofibromatosis Program
Key Takeaways
- Pasithea Therapeutics (KTTA) shares climbed roughly +31% over the 30 days through early November, from about $0.44 to approximately $0.58.
- The main catalyst was the U.S. FDA's November 3 clearance of an Investigational New Drug (IND) application for PAS-004 in neurofibromatosis type 1 (NF1)-associated cutaneous neurofibromas (cNF), enabling a planned Phase 2 trial.
- PAS-004 is a next-generation macrocyclic oral MEK inhibitor; cNF affects more than 95% of people with NF1, and there are currently no FDA-approved systemic therapies for the condition.
- The stock remains highly volatile: it slid from about $0.58 in early September to a late-October trough near $0.37 before rebounding sharply on the regulatory news.
- Near-term catalysts include initial Phase 1/1b NF1 data at the European Neurofibromatosis Conference (November 12–14) and the company's third-quarter earnings report.
- For deeper data on valuation, fundamentals, and forward estimates, explore Pasithea's Price Targets, Earnings, and Forecast pages.
- To see how algorithmic strategies are positioning in names like KTTA, explore Trending AI Robots.
Company Overview for Pasithea Therapeutics (KTTA)
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company based in Miami Beach, Florida, that focuses on treatments for RASopathies, MAPK pathway-driven tumors, and other conditions including central nervous system disorders. Its lead asset, PAS-004, is a next-generation macrocyclic oral MEK inhibitor intended for convenient once-daily chronic use. The company is running a Phase 1 study in advanced solid tumors and a Phase 1/1b study in adult NF1 patients with plexiform neurofibromas, while now preparing a Phase 2 program in NF1-associated cutaneous neurofibromas. It also holds FDA Fast Track and Rare Pediatric Disease designations for PAS-004 in NF1-PN plus Orphan Drug Designation for ALS. Most investors track the name for clinical readouts and regulatory updates tied to this pipeline.
KTTA Stock Performance Over the Past 30 Days and Quarter
Over the most recent 30 days, KTTA rose approximately +31%, moving from a close near $0.44 in early October to roughly $0.58 in early November. The advance was abrupt rather than steady; shares had lingered in the low-$0.40 range through much of October before surging on November 3, when volume spiked to around 10 million shares against a usual daily range of 50,000 to 400,000.
Looking at the broader quarter, the picture shows more volatility. From a close near $0.58 in early September the stock drifted lower through October, touching a low around $0.37 late in the month. The November rebound returned it to roughly the early-September level, leaving the name essentially flat for the full quarter after a notable drawdown and recovery. This pattern is typical for a small-cap clinical-stage biotech where binary news events dominate price action.
Key Drivers Behind the Recent 30-Day Move
The primary driver was the FDA clearance of the IND application for PAS-004 in NF1-associated cutaneous neurofibromas, announced November 3. The clearance supports a randomized, placebo-controlled Phase 2 trial in the United States for a condition that affects more than 95% of NF1 patients and currently lacks any approved systemic therapies. The company has estimated more than 80,000 people in the U.S. have moderate-to-severe NF1-associated cNF. This expansion beyond plexiform neurofibromas widened the potential market for PAS-004 and prompted the sharp re-rating accompanied by heavy volume.
Additional attention came from a virtual key opinion leader event on NF1 scheduled for November 4 featuring experts from the University of Alabama at Birmingham and Stanford. The company also plans to present initial Phase 1/1b data in adult NF1 patients at the European Neurofibromatosis Conference in mid-November, keeping another near-term catalyst in sight. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Performance Drivers Across the Full Quarter
Over the quarter, KTTA faced downward pressure for much of the period before the November rebound. A $60 million public offering that closed in early December 2025, issuing 80 million shares at $0.75 to investors including Vivo Capital, Janus Henderson, Coastlands Capital, Columbia Threadneedle, Adage Capital Partners, and Squadron Capital, created a dilution overhang that weighed on the stock into 2026. Despite positive pipeline updates such as interim Phase 1 data in advanced cancer, protocol amendments, an ESMO 2026 poster, and regulatory designations, the shares drifted lower until the October low, which coincided with broader weakness in small-cap biotech. The IND clearance then restored momentum and brought the price back in line with early-September levels.
Near-Term Catalysts and Outlook for KTTA
Several upcoming events merit attention. Pasithea will present initial Phase 1/1b Part A data in adult NF1 patients at the European Neurofibromatosis Conference in Vienna November 12–14, marking the first public look at that dataset. Third-quarter earnings are expected in mid-November, with analysts forecasting a loss of about $0.21 per share. Progress on the newly cleared cNF Phase 2 trial and continued dose escalation in the advanced-cancer study will also be watched. H.C. Wainwright has reiterated a Buy rating with a $3.00 price target, and the consensus stands at Moderate Buy. As a pre-revenue clinical-stage company, KTTA will continue to react to clinical data, regulatory decisions, financing needs, and overall biotech sentiment.
Exploring Algorithmic Strategies in Biotech Names
In my own work following clinical-stage names, I occasionally review Tickeron’s Trending AI Robots to see how different automated strategies are positioned across the sector. The page highlights top-performing bots with varying timeframes and approaches, which can offer a useful complement to fundamental analysis when evaluating volatility around events like regulatory clearances.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KTTA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for KTTA turned positive on November 03, 2026. Looking at past instances where KTTA's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on KTTA as a result. In 70 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
KTTA moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where KTTA advanced for three days, in 141 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KTTA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KTTA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. KTTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.388) is normal, around the industry mean (3.498). P/E Ratio (-0.429) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement